992 related articles for article (PubMed ID: 16861943)
61. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
González-Roncero FM; Gentil-Govantes MÁ; González-Molina M; Rivero M; Cantarell C; Alarcón A; Franco A; Sánchez-Plumed J; Lampreabe I; Lauzurica R; González E; Romero R; Ruiz-San Millán JC; Osuna A
Nefrologia; 2012 Jul; 32(4):446-54. PubMed ID: 22806279
[TBL] [Abstract][Full Text] [Related]
62. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial.
Welberry Smith MP; Cherukuri A; Newstead CG; Lewington AJ; Ahmad N; Menon K; Pollard SG; Prasad P; Tibble S; Giddings E; Baker RJ
Transplantation; 2013 Dec; 96(12):1082-8. PubMed ID: 24056618
[TBL] [Abstract][Full Text] [Related]
63. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
64. Campath-1H in renal transplantation: The University of Wisconsin experience.
Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
[TBL] [Abstract][Full Text] [Related]
65. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
[TBL] [Abstract][Full Text] [Related]
66. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
[TBL] [Abstract][Full Text] [Related]
67. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction.
Cantarovich D; Rostaing L; Kamar N; Saint-Hillier Y; Ducloux D; Mourad G; Garrigue V; Wolf P; Ellero B; Cassuto E; Albano L; Soulillou JP;
Transpl Int; 2010 Mar; 23(3):313-24. PubMed ID: 19843296
[TBL] [Abstract][Full Text] [Related]
68. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
Leichtman AB
N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
[No Abstract] [Full Text] [Related]
69. Calcineurin-inhibitor-sparing immunosuppressive protocols.
Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3729-32. PubMed ID: 16386520
[TBL] [Abstract][Full Text] [Related]
70. Calcineurin inhibitor avoidance versus steroid avoidance following kidney transplantation: Postoperative complications.
Shaffer D; Kizilisik AT; Feurer I; Nylander WA; Helderman JH; Langone AJ; Schaefer HM
Transplant Proc; 2006 Dec; 38(10):3464-5. PubMed ID: 17175304
[TBL] [Abstract][Full Text] [Related]
71. Correlations with six-month protocol biopsy findings in pediatric transplant recipients on low- and regular-dose CNI regimens.
Kanzelmeyer NK; Ahlenstiel T; Kreuzer M; Becker JU; Pape L
Clin Transplant; 2013; 27(2):319-23. PubMed ID: 23414365
[TBL] [Abstract][Full Text] [Related]
72. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
[No Abstract] [Full Text] [Related]
73. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.
Ruggenenti P; Perico N; Gotti E; Cravedi P; D'Agati V; Gagliardini E; Abbate M; Gaspari F; Cattaneo D; Noris M; Casiraghi F; Todeschini M; Cugini D; Conti S; Remuzzi G
Transplantation; 2007 Oct; 84(8):956-64. PubMed ID: 17989600
[TBL] [Abstract][Full Text] [Related]
74. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
Dresske B; Zavazava N; Jenisch S; Exner B; Lenz P; El Mokhtari NE; Kremer B; Faendrich F
Transplantation; 2003 Apr; 75(8):1286-91. PubMed ID: 12717217
[TBL] [Abstract][Full Text] [Related]
75. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients.
Kim SJ; Lee KW; Lee DS; Lee HH; Lee SK; Kim B; Huh WS; Oh HY; Joh JW
Transplant Proc; 2004 Sep; 36(7):2098-100. PubMed ID: 15518759
[TBL] [Abstract][Full Text] [Related]
76. Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation-A single center matched cohort study.
Leiskau C; Rajanayagam J; Pfister ED; Goldschmidt I; Junge N; Karch A; Lerch C; Richter N; Lehner F; Schrem H; Baumann U
Pediatr Transplant; 2018 Aug; 22(5):e13207. PubMed ID: 29729061
[TBL] [Abstract][Full Text] [Related]
77. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Kupin W; Rosen A; Cordovilla T; Tueros L; Herrada E; Miller J
Clin Transplant; 2008; 22(2):200-10. PubMed ID: 18339140
[TBL] [Abstract][Full Text] [Related]
78. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study.
Beckebaum S; Cicinnati VR; Klein CG; Brokalaki E; Yu Z; Malago M; Frilling A; Gerken G; Broelsch CE
Transplant Proc; 2004 Nov; 36(9):2671-4. PubMed ID: 15621120
[TBL] [Abstract][Full Text] [Related]
79. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
[TBL] [Abstract][Full Text] [Related]
80. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation.
Ahsan N; Holman MJ; Jarowenko MV; Razzaque MS; Yang HC
Am J Transplant; 2002 Jul; 2(6):568-73. PubMed ID: 12118902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
